Standard BioTools Inc. Accumulated Other Comprehensive Income
Standard BioTools Inc. (LAB) had Accumulated Other Comprehensive Income of $1.18 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.18M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$511.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.49M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$477.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $1.18M 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$511.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$1.49M 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$477.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$1.93M 10-Q · filed 2025-08-15 |
| 2025-03-31 | $1.17M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.23M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$1.41M 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$1.50M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$1.79M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$2.22M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$1.95M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$1.55M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$1.33M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$1.90M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$2.61M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$2.25M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$1.06M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$907.00K 10-K · filed 2023-03-14 |
| 2021-09-30 | -$730.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$284.00K 10-Q · filed 2021-08-06 |
| 2021-03-31 | -$331.00K 10-Q · filed 2021-05-07 |
| 2020-12-31 | $112.00K 10-K · filed 2022-03-08 |
| 2020-09-30 | -$289.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$809.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | -$885.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$582.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | -$758.00K 10-Q · filed 2019-11-08 |
| 2019-06-30 | -$623.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$677.00K 10-Q · filed 2019-05-07 |
| 2018-12-31 | -$687.00K 10-K · filed 2020-02-27 |
| 2018-09-30 | -$516.00K 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$504.00K 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$532.00K 10-Q · filed 2018-05-08 |
| 2017-12-31 | -$574.00K 10-K · filed 2019-03-18 |
| 2017-09-30 | -$731.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$648.00K 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$725.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$760.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | -$911.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$858.00K 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$885.00K 10-Q · filed 2016-05-09 |
| 2015-12-31 | -$1.14M 10-K · filed 2017-03-03 |
| 2015-09-30 | -$794.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | -$697.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | -$600.00K 10-Q · filed 2015-05-11 |
| 2014-12-31 | -$794.00K 10-K · filed 2016-02-29 |
| 2014-09-30 | -$802.00K 10-Q · filed 2014-11-06 |
| 2014-06-30 | -$700.00K 10-Q · filed 2014-08-04 |
| 2014-03-31 | -$757.00K 10-Q · filed 2014-05-12 |
| 2013-12-31 | -$730.00K 10-K · filed 2015-02-26 |
| 2013-09-30 | -$713.00K 10-Q · filed 2013-11-07 |
| 2013-06-30 | -$795.00K 10-Q · filed 2013-08-07 |
| 2013-03-31 | -$772.00K 10-Q · filed 2013-05-09 |
| 2012-12-31 | -$769.00K 10-K · filed 2014-03-12 |
| 2012-09-30 | -$774.00K 10-Q · filed 2012-11-09 |
| 2012-06-30 | -$782.00K 10-Q · filed 2012-08-14 |
| 2012-03-31 | -$777.00K 10-Q · filed 2012-05-15 |
| 2011-12-31 | -$754.00K 10-K · filed 2013-03-12 |
| 2011-09-30 | -$742.00K 10-Q · filed 2011-11-14 |
| 2011-06-30 | -$774.00K 10-Q · filed 2011-08-09 |
| 2010-12-31 | -$778.00K 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |